Toggle SGML Header (+)


Section 1: 8-K (FORM 8-K)

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________

Form 8-K
_____________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): October 23, 2018  

PSYCHEMEDICS CORPORATION
(Exact Name of Registrant as Specified in Charter)

Deleware1-1373858-1701987
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification Number)

 

289 Great Road, Acton, Massachusetts 01720
(Address of Principal Executive Offices) (Zip Code)

(978) 206-8220
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 [ ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 [ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 [ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 [ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company [   ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [   ]

 
 

Item 2.02. Results of Operations and Financial Condition.

On October 23, 2018, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Limitation on Incorporation by Reference. The information in this Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

Cautionary Note Regarding Forward-Looking Statements. Except for historical information contained in the press release attached as an exhibit hereto, the press release contains forward-looking statements which involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. Please refer to the cautionary note in the press release regarding these forward-looking statements.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1. Press release dated October 23, 2018


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 PSYCHEMEDICS CORPORATION
   
  
Date: October 23, 2018By: /s/ Neil Lerner        
  Neil Lerner
  Vice President, Finance
  

(Back To Top)

Section 2: EX-99.1 (PRESS RELEASE)

EdgarFiling

EXHIBIT 99.1

Psychemedics Announces Quarterly Results

Declares 89th Consecutive Quarterly Dividend

ACTON, Mass., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced third quarter financial results for the period ended September 30, 2018.  The Company also announced a quarterly dividend of $0.18 per share payable to shareholders of record as of November 2, 2018, to be paid on November 12, 2018.  This will be the Company’s 89th consecutive quarterly dividend.

The Company’s revenue for the quarter ended September 30, 2018 was $11.0 million versus $10.0 million for the comparable period in 2017, an increase of 10%.  Net income for the quarter ended September 30, 2018 was $1.3 million or $0.23 per diluted share, versus $1.4 million or $0.25 per diluted share, for the comparable period last year, a decrease of 7%.  Revenue for the nine months ended September 30, 2018 was $32.7 million versus $29.9 million for the comparable period in 2017, an increase of 9%.  Net income for the nine months ended September 30, 2018 was $3.7 million or $0.67 per diluted share versus $3.8 million or $0.68 per diluted share, for the comparable period last year, a decrease of 2%.

Raymond C. Kubacki, Chairman and Chief Executive Officer, said,

"Third quarter volumes and revenues continued to show strong growth.  However, these strong results (revenues and earnings) were masked by the unfavorable impact from foreign currency exchange rates. 

“Total revenue growth was 10%.  Excluding the exchange rate impact, total revenue would have been up 15%.  Our domestic revenues continued to show strong growth, which was largely attributable to our Oil & Gas, Transportation and Manufacturing market segments.  Our international business (primarily Brazil) was up 9%. International revenue would have been up 26% for the quarter compared to the same period in 2017, if the exchange rate had remained constant.    

"Earnings were also impacted by the change in exchange rate.   Had the exchange rate for the quarter remained the same as the third quarter of 2017, net income would have been approximately $1.6 million or $0.29 per diluted share which would have reflected an increase of 16%.  In response to these foreign exchange rate fluctuations, we came to an agreement with the company’s Brazilian distributor to now share in the foreign exchange risk.     

"We have stated for several quarters that we were expecting an expansion of the Brazil market in the fourth quarter this year when professional drivers were required to renew their licenses every 2 1/2 years instead of the current 5 years.  This expansion is by law and will virtually double the market size as it unfolds.  However, the implementation of this law can be temporarily delayed, and it now appears this is the case, due to the elections in Brazil.  We expect that this market expansion will take place in 2019.

“The Company’s balance sheet remains strong with $6.0 million in cash and $9.8 million of working capital.  The total equipment financing obligation outstanding was $2.7 million as of September 30, 2018.  Our directors share our confidence in the future of Psychemedics and remain committed to rewarding shareholders and sharing the financial success of the Company with them as we grow.  Therefore, we are pleased to declare our quarterly dividend $0.18 per share. This dividend represents our 89th consecutive quarterly dividend.”

Contact:
Neil Lerner
Vice President of Finance
(978) 206-8220
Neill@psychemedics.com

Psychemedics Corporation is the world’s largest provider of hair testing for the detection of drugs of abuse. The Company’s patented process is used by thousands of U.S. and international clients, including over 10% of the Fortune 500 companies, for pre-employment and random drug testing. Major police departments, Federal Reserve Banks, schools, and other public entities also rely on our unique patented drug testing process. We strongly believe our drug testing method to be superior to any other product currently in use, including traditional urine testing and other hair testing methods.

The Psychemedics web site is www.psychemedics.com

Cautionary Statement for purposes of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995:  From time to time, information provided by Psychemedics may contain forward-looking information that involves risks and uncertainties.  In particular, statements contained in this release that are not historical facts (including but not limited to statements concerning earnings, earnings per share, revenues, cash flows, dividends, future business, growth opportunities, profitability, pricing, new accounts, customer base, market share, test volume, sales and marketing strategies, U.S. and foreign drug testing laws and regulations and the enforcement of such laws and regulations, required investments in plant, equipment and people and new test development) may be "forward looking" statements.  Actual results may differ from those stated in any forward-looking statements.  Factors that may cause such differences include but are not limited to risks associated with the development of markets for new products and services offered, costs of capacity expansion, U.S. and foreign government regulation, including but not limited to FDA regulations, Brazilian laws and regulations, proposed laws and regulations, currency risks, R&D spending, competition (including, without limitation, competition from other companies pursuing the same growth opportunities), the Company’s  ability to maintain its reputation and brand image, the ability of the Company to achieve its business plans, cost controls, leveraging of its global operating platform,  risks of information technology system failures and data security breaches, the uncertain global economy, the Company’s  ability to attract, develop and retain executives and other qualified employees and independent contractors, including distributors, the Company’s ability to obtain and protect intellectual property rights, litigation risks, general economic conditions and other factors disclosed in the Company's filings with the Securities and Exchange Commission.  The forward-looking statements contained herein speak only of the Company's expecta­tions as of the date of this press release. The Company express­ly disclaims any obligation or undertaking to release publicly any updates or revi­sions to any such statement to reflect any change in the Company's expectations or any change in events, conditions, or circumstances on which any such statement is based.

 
Psychemedics Corporation
Consolidated Statements of Income
(in thousands, except per share amounts)
(UNAUDITED)
 
 Three Months Ended Nine Months Ended
 September 30, September 30,
  2018   2017  2018  2017 
        
        
Revenue$11,016  $10,049 $32,738 $29,942 
Cost of revenue 5,658   4,928  16,853  14,896 
        
Gross profit 5,358   5,121  15,885  15,046 
        
        
Operating Expenses:       
General & administrative 1,599   1,471  4,907  4,278 
Marketing & selling 1,267   1,065  3,807  3,552 
Research & development 372   353  1,089  1,005 
        
Total Operating Expenses 3,238   2,889  9,803  8,835 
        
Operating income 2,120   2,232  6,082  6,211 
Other income (expense) (9)   13  47  (22) 
        
Net income before provision for income taxes 2,111   2,245  6,129  6,189 
        
Provision for income taxes 836   881  2,426  2,418 
        
Net income$1,275  $1,364 $3,703 $3,771 
        
Diluted net income per share$0.23  $0.25 $0.67 $0.68 
        
Dividends declared per share$0.18  $0.15 $0.54 $0.45 
        


Psychemedics Corporation
Consolidated Balance Sheets
(in thousands, except par value)
(UNAUDITED)
 
 September 30, December 31,
  2018   2017 
    
ASSETS   
Current Assets:   
Cash and cash equivalents$6,016  $8,165 
Accounts receivable, net of allowance for doubtful accounts   
of $71 in 2018 and $64 in 2017 8,067   4,488 
Prepaid expenses and other current assets 1,359   1,212 
Total Current Assets 15,442   13,865 
    
Fixed Assets, net of accumulated amortization and depreciation   
of $13,712 in 2018 and $11,670 in 2017 10,644   11,811 
Other assets 900   832 
    
Total Assets$26,986  $26,508 
    
LIABILITIES AND SHAREHOLDERS' EQUITY   
    
Current Liabilities:   
Accounts payable$813  $398 
Accrued expenses 3,908   2,870 
Current portion of long-term debt 941   957 
    
Total Current Liabilities 5,662   4,225 
    
Long-term debt 1,719   2,420 
Deferred tax liabilities, long-term 1,091   1,243 
Total Liabilities 8,472   7,888 
    
Shareholders' Equity:   
Common stock, $0.005 par value; 50,000 shares authorized   
6,175 shares issued in 2018 and 6,160 shares issued in 2017 31   31 
Accumulated other comprehensive loss (1,584)   (238) 
Additional paid-in capital 31,365   31,022 
Accumulated deficit (1,216)   (2,113) 
Less - Treasury stock, at cost, 668 shares (10,082)   (10,082) 
    
Total Shareholders' Equity 18,514   18,620 
    
Total Liabilities and Shareholders' Equity$26,986  $26,508 
    

(Back To Top)